Skip to content
Proof Line Peptides
0
Journal

Understanding evidence

Reading a peptide study: population, comparator, endpoint and follow-up

By Proof Line Peptides · Published · 2 min read

Four questions answer most of what an abstract can support: who was studied, what they were compared against, what was measured, and for how long. Answer those before reading anyone’s summary of the result.

Population: who was actually enrolled

Populations are narrow on purpose. A 2007 randomized trial of tesamorelin enrolled 412 patients with HIV and abdominal fat accumulation, and a 2021 trial of semaglutide enrolled 1,961 adults with overweight or obesity without diabetes alongside a lifestyle intervention. Those are different questions with different answers. [Falutz et al., 2007][Wilding et al., 2021 (STEP 1)]

Comparator: compared with what

Without a comparator, change over time can reflect the natural course, measurement drift or co-interventions. Placebo-controlled randomized designs — such as the 48-week phase 2 retatrutide trial — exist to separate the intervention from everything else happening to participants. [Jastreboff et al., 2023]

Endpoint: what was measured

Endpoints can be specific and narrower than the headline suggests. A visceral-fat measure is not general weight loss; a laboratory marker is not a symptom; and an indication in a regulated label is written for a defined population, as in United States bremelanotide labelling limited to acquired, generalized hypoactive sexual desire disorder in premenopausal women, with stated exclusions. [Falutz et al., 2007][US bremelanotide prescribing information]

Follow-up: for how long

Durations in these reports range from roughly six months to over a year. A 26-week or 48-week result says nothing certain about year three, and a short study cannot characterise effects that emerge slowly or resolve quickly. [Falutz et al., 2007][Jastreboff et al., 2023]

One-sentence discipline

  1. Write: in [population], over [duration], [intervention] versus [comparator] showed [endpoint result].
  2. Add the reported harms in the same sentence or the next one.
  3. Name the publication year and study stage exactly as reported.
  4. Do not substitute a product you can buy for the product that was studied.

Frequently asked

Is an abstract enough to appraise a study?
An abstract supports a narrow, carefully worded statement about the reported design and result. Details of methods, analysis and harms usually require the full report.
Why does the publication year matter so much?
It anchors the claim in time. Describing a 2023 phase 2 report as the current state of a research programme adds information the source does not contain.
Can trial results be applied to a research vial with the same ingredient name?
No. Trials study a specific manufactured product under controlled conditions. A laboratory research material is a different product with its own, separate documentation.

References

  1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. doi:10.1056/NEJMoa072375 View source
  2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. doi:10.1056/NEJMoa2032183 View source
  3. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023. doi:10.1056/NEJMoa2301972 View source
  4. Official United States prescribing information for bremelanotide injection (Vyleesi), revised March 2024. United States labelling only. View source